TY  - BOOK
AU  - Manar Saad Mohamed Ramadan
AU  - Ahmed Abdelraheem Alnagar , 
AU  - Hanan Ezzat Shafik , 
AU  - Nevine Fayez Habashy , 
TI  - Prognostic factors in metastatic renal cell carcinoma patients in relation to targeted therapy / 
PY  - 2019///
CY  - Cairo : 
PB  - Manar Saad Mohamed Ramadan , 
KW  - Metastatic renal cell carcinoma
KW  - Pazopanib
KW  - Sunitinib
N1  - Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology-Medical; Issued also as CD
N2  - Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women, respectively with renal cell carcinoma (RCC) accounts for {u223C} 80% of all kidney cancers. Several agents targeting the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway were progressively approved for first-line or later-line use in the treatment of patients with advanced RCC and became the new standard of care. The aim of the study is to clarify the clinical and pathological features of metastatic renal cell carcinoma (RCC) cases and correlate the use of targeted therapy with the outcome and survival. Our study included 73 patients diagnosed and managed at medical oncology department of National cancer institute (NCI), Cairo university and Zagazig University Hospitals with 59 patients received targeted therapy after radical nephrectomy and 14 patients had only radical nephrectomy. The study was approved by the institutional review board (IRB), of NCI, Egypt. The overall response rate (RR) was 39% with the median follow up duration was 22.4 months (Range 1.13-64.2) while the overall disease control rate (DCR) was 79.7%. Median overall survival was 32.6 months while median progression free survival (PFS) was 12.7 months. Patients who received targeted therapy had a significant impact on OS, PFS and RR with sunitinib showed better survival than pazopanib as first line, but didn{u2019}t affect the response. The IMDC prognostic model had a better significant relation with the response and survival than MSKCC model
UR  - http://172.23.153.220/th.pdf
ER  -